Trestle Biotherapeutics
Bioengineered kidneys for patients with kidney failure
What they do
Patients with end stage renal disease depend on dialysis while waiting for kidney transplants, facing major burden and limited renal function.
An implantable bioengineered kidney tissue therapy that supplements renal function to reduce or eliminate dialysis dependence and delay the need for transplant.
End stage renal disease patients treated by transplant and nephrology teams in hospitals and specialty clinics.
Founders
Co-founder, Chief Executive Officer. Dr. Shepherd is a vascular biologist, tissue engineer and regenerative medicine scientist by training. He has spent the past 10+ years in industry since leaving his academic position at the Yale School of Medicine. He has built successful research teams focused on using 3D bioprinting and biofabrication to develop both in vitro human tissue systems and translational approaches to creating therapeutic tissues.
Entrepreneur with 20+ years research experience in the fields of developmental biology, stem cell biology, and tissue engineering. Founded Trestle Biotherapeutics to develop a functional therapeutic tissue for patients suffering from Chronic Kidney Disease through the successful integration of stem cell biology and biofabrication.
Company timeline
- Founded2020
- YC batchWinter 2021
- StatusActive
- Team size2 people
- LocationSan Diego, CA, USA
